136 related articles for article (PubMed ID: 10545015)
21. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
[TBL] [Abstract][Full Text] [Related]
22. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT.
Somers VA; Pietersen AM; Theunissen PH; Thunnissen FB
J Clin Oncol; 1998 Sep; 16(9):3061-8. PubMed ID: 9738576
[TBL] [Abstract][Full Text] [Related]
23. Molecular analysis of peritoneal fluid in ovarian cancer patients.
Parrella P; Zangen R; Sidransky D; Nicol T
Mod Pathol; 2003 Jul; 16(7):636-40. PubMed ID: 12861058
[TBL] [Abstract][Full Text] [Related]
24. K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus.
Trautmann B; Wittekind C; Strobel D; Meixner H; Keymling J; Gossner L; Ell C; Hahn EG
Eur J Gastroenterol Hepatol; 1996 Aug; 8(8):799-804. PubMed ID: 8864678
[TBL] [Abstract][Full Text] [Related]
25. Low incidence of H-, K- and N-ras oncogene mutations in cytological specimens of laryngeal tumours.
Rizos E; Sourvinos G; Arvanitis DA; Velegrakis G; Spandidos DA
Oral Oncol; 1999 Nov; 35(6):561-3. PubMed ID: 10705090
[TBL] [Abstract][Full Text] [Related]
26. Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas.
Urban T; Ricci S; Grange JD; Lacave R; Boudghene F; Breittmayer F; Languille O; Roland J; Bernaudin JF
J Natl Cancer Inst; 1993 Dec; 85(24):2008-12. PubMed ID: 7902444
[TBL] [Abstract][Full Text] [Related]
27. Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.
Broermann P; Junker K; Brandt BH; Heinecke A; Freitag L; Klinke F; Berdel WE; Thomas M
Cancer; 2002 Apr; 94(7):2055-62. PubMed ID: 11932909
[TBL] [Abstract][Full Text] [Related]
28. [K-ras gene mutation in gallbladder carcinoma].
Roa JC; Roa I; de Aretxabala X; Melo A; Faría G; Tapia O
Rev Med Chil; 2004 Aug; 132(8):955-60. PubMed ID: 15478297
[TBL] [Abstract][Full Text] [Related]
29. Detection of K-ras mutations by denaturing gradient gel electrophoresis (DGGE): a study on pancreatic cancer.
Pellegata NS; Losekoot M; Fodde R; Pugliese V; Saccomanno S; Renault B; Bernini LF; Ranzani GN
Anticancer Res; 1992; 12(5):1731-5. PubMed ID: 1444240
[TBL] [Abstract][Full Text] [Related]
30. Ras oncogene activation in benign and malignant colorectal tumours.
Spandidos DA; Glarakis IS; Kotsinas A; Ergazaki M; Kiaris H
Tumori; 1995; 81(3 Suppl):7-11. PubMed ID: 7571058
[TBL] [Abstract][Full Text] [Related]
31. K-ras point mutation occurs in the early stage of carcinogenesis in lung cancer.
Sagawa M; Saito Y; Fujimura S; Linnoila RI
Br J Cancer; 1998 Mar; 77(5):720-3. PubMed ID: 9514049
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium.
Manavi M; Bauer M; Baghestanian M; Berger A; Kucera E; Pischinger K; Battistutti W; Czerwenka K
Tumour Biol; 2001; 22(5):299-309. PubMed ID: 11553860
[TBL] [Abstract][Full Text] [Related]
33. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential.
Haas CJ; Diebold J; Hirschmann A; Rohrbach H; Löhrs U
Virchows Arch; 1999 Feb; 434(2):117-20. PubMed ID: 10071245
[TBL] [Abstract][Full Text] [Related]
34. K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
Enomoto T; Inoue M; Perantoni AO; Buzard GS; Miki H; Tanizawa O; Rice JM
Cancer Res; 1991 Oct; 51(19):5308-14. PubMed ID: 1913654
[TBL] [Abstract][Full Text] [Related]
35. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
[TBL] [Abstract][Full Text] [Related]
36. Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors.
Morita K; Ono Y; Fukui H; Tomita S; Ueda Y; Terano A; Fujimori T
Pathol Int; 2000 Mar; 50(3):219-23. PubMed ID: 10792785
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of K-ras oncogene activation in ampullary neoplasms.
Chung CH; Wilentz RE; Polak MM; Ramsoekh TB; Noorduyn LA; Gouma DJ; Huibregtse K; Offerhaus GJ; Slebos RJ
J Clin Pathol; 1996 Jun; 49(6):460-4. PubMed ID: 8763258
[TBL] [Abstract][Full Text] [Related]
38. K-ras and rho A mutations in malignant pleural effusion.
Nakamoto M; Teramoto H; Matsumoto S; Igishi T; Shimizu E
Int J Oncol; 2001 Nov; 19(5):971-6. PubMed ID: 11604996
[TBL] [Abstract][Full Text] [Related]
39. Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan.
Wu CM; Tang R; Wang JY; Changchien CR; Hsieh LL
Cancer Genet Cytogenet; 2005 Apr; 158(1):55-60. PubMed ID: 15771905
[TBL] [Abstract][Full Text] [Related]
40. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer.
Esteller M; García A; Martínez-Palones JM; Xercavins J; Reventós J
Eur J Cancer; 1997 Sep; 33(10):1572-7. PubMed ID: 9389917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
